Improving clinical translational for ADCs and immuno-oncology with human-relevant tumor
Evaluating ADCs and immuno-oncology therapies in models that accurately reflect human biology remains a critical challenge in translational research.
If you missed the live discussion, you can now access the full session on-demand!
@Seahee Kim, Ph.D., Director of Organoids Technology Group at Samsung Biologics, walks through how patient-derived tumor organoids can help bridge this gap — providing a human-relevant platform to better predict clinical outcomes.
Key takeaways from the session:
Patient-derived tumor organoids as human-relevant models for ADC & immuno-oncology evaluation
Integrated assessment from target expression & internalization to cellular uptake & tumor cell killing
Immune cell co-culture assays for immune activation, cytokine secretion & tumor cell killing, incl. T-cell engagers
Evaluating ADCs and immuno-oncology therapies in models that accurately reflect human biology remains a critical challenge in translational research.
If you missed the live discussion, you can now access the full session on-demand!
@Seahee Kim, Ph.D., Director of Organoids Technology Group at Samsung Biologics, walks through how patient-derived tumor organoids can help bridge this gap — providing a human-relevant platform to better predict clinical outcomes.
Key takeaways from the session:
Patient-derived tumor organoids as human-relevant models for ADC & immuno-oncology evaluation
Integrated assessment from target expression & internalization to cellular uptake & tumor cell killing
Immune cell co-culture assays for immune activation, cytokine secretion & tumor cell killing, incl. T-cell engagers
Related Content